Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

Tariff turmoil prompts cloudy forecasts from companies for the year ahead

Uncertainty continues to hang over the latest round of financial results and forecasts for companies both big and small as they try to navigate a global trade system severely shaken by a stark shift in U.S. policy

The Independent UK

Wall Street falls while FTSE 100 regains losses after US economy shrinks

The American economy contracted by 0.3% in the first three months of the year amid Donald Trump’s threats of sweeping trade tariffs.

Evening Standard

GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs

GSK stock jumped Wednesday after the British drugmaker said it's "well positioned" to respond if the U.S. levies tariffs on drug imports.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Drugs giant GSK ‘well positioned’ to absorb potential US tariffs

It came as the FTSE 100 giant revealed a rise in sales as weakness in its vaccine division was offset by growth in speciality medicines.

Evening Standard

The impact Trump’s tariffs could have on the NHS

IN FULL

The Independent UK

Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS?

TRUMP TARIFFS: UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports

The Independent UK

EU drug companies warn of exodus to US as Trump threatens import tariffs

Von der Leyen urged to take ‘rapid and radical action’ as president says tariffs on pharmaceuticals coming ‘shortly’

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Trump tariffs: Which UK sectors will be hit hardest?

The PA news agency looks at which sectors will be most affected by the plans and what it means for businesses and households.

Evening Standard

Shingles vaccine tied to a 20% lower risk of dementia among older people

The findings add to a growing body of evidence that the shingles vaccine may help keep dementia at bay – but researchers still need to prove it.

Euronews

GSK employees perform anonymous ‘180’ surveys on their bosses, and CEO Emma Walmsley isn’t exempt

Emma Walmsley says her "180" would probably tell her to say "thank yous" and "well dones."

Fortune

FDA approves new UTI antibiotic that may help patients with recurring infections

A commercial launch of the antibiotic in the U.S. is planned during the second half of 2025

The Independent UK

New Antibiotics For UTI Gets FDA Approval- First In 30 Years

The FDA has approved a new antibiotic, Gepotidacin (Blujepa), for treating uncomplicated urinary tract infections (UTIs) in women and girls aged 12 and older.

Medical Daily

From $6 billion unicorn to bankrupt cautionary tale: The story of 23andMe

DNA testing company 23andMe was a white-hot Silicon Valley startup for years, and Anne Wojcicki was a celebrity CEO. But after going public, investors lost faith in the DNA testing company.

Fortune

Pfizer offloads final shares in Sensodyne maker Haleon

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Doctors didn’t warn ‘deviant sexual behaviour’ was side effect of restless legs syndrome drug

Patients claim GPs did not tell them about significant potential side effects of treatment

Fortune

Power Players: Meet the women reshaping 10 key European industries

This year, Fortune curated a list of female leaders at the helm of European companies across the continent’s biggest industries.

Fortune

23andMe was once worth $6 billion. Now CEO Anne Wojcicki wants to buy it back for $42 million

Experts say the CEO’s second attempt to buy back the troubled DNA startup comes with a slew of corporate governance red flags.

The Guardian - UK

British pharma company GSK pauses diversity work citing Trump orders

London-based FTSE 100 firm reviewing its policies, saying it is obliged to comply because US is its No 1 market

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

GSK could double CEO Emma Walmsley's pay to $27 million

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

The Guardian - UK

GSK boss Emma Walmsley’s pay could rise to nearly £22m in three years’ time

UK pharmaceutical companies aim to put executive pay on par with US rivals’ but package will depend on share price

The Guardian - UK

Women hold almost 45% of seats on FTSE 100 boards, report says

New high tempered by dip in number of female CEOs at 100 biggest listed firms to fewer than 10 last year

The Guardian - UK

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

Investors Business Daily

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were losers.

International Business Times UK

Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

The Guardian - UK

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.